Seeking Alpha

Targacept (TRGT -32.1%) catches the eye of analysts a bit late after the firm bombs with Phase...

Targacept (TRGT -32.1%) catches the eye of analysts a bit late after the firm bombs with Phase III clinical results for its antidepressant drug-candidate TC-5214. Leerink Swann downgrades shares to Market Perform from Outperform, while Global Hunter takes its rating down to Neutral from Accumulate.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs